Right from
the start

Navitor™ TAVI – the index valve that preserves options,
sustains hemodynamics and delivers predictably

Right from the start

Navitor™ TAVI – the index valve that preserves options, sustains hemodynamics and delivers predictably

Considerations for
the index valve choice

1

Will the valve preserve coronary access, durability, and future treatment options?

The Navitor™ valve intra-annular, cylindrical design and 360º large cells preserve coronary access, future treatment options, and show strong durability signals at 5 years.1

2

Will the valve perform, and keep performing?

The Navitor valve shows low gradients, large EOA and minimal PPM across all sizes at 30 days, through 5 years. Sealing is predictable, even with heavy calcium, minimizing PVL.1

3

Can I safely get the valve where it needs to go?

Navitor™ TAVI is designed for safe navigation, even in complex anatomies, with precise implantation and full deployment control—supported by the FlexNav™ delivery system.2

Navitor TAVI 5-year data1

Navitor TAVI 5-year data1

6.8mmHG2.0cm23.7%0%0.6%
Mean gradientEffective Orifice 
Area (EOA) 		Bioprosthetic Valve Dysfunction (BVD)Moderate or Severe Hemodynamic 
Structural Valve Deterioration (HSVD)		Aortic Valve Reintervention

6.8mmHG
Mean gradient
 

2.0cm2
Effective Orifice
Area (EOA)
 

3.7%
Bioprosthetic Valve Dysfunction (BVD)
 

0%
Moderate or Severe Hemodynamic
Structural Valve Deterioration (HSVD)
 

0.6%
Aortic Valve Reintervention
 

Explore Navitor TAVI

Valve
technology

Design features that support
performance, sealing, and future options

Explore valve technology
 

 

Delivery
system

FlexNav innovation for predictable
navigation and placement

Explore the delivery system
 

 

Clinical
outcomes

Proven endpoints and outcomes across clinical trials

View clinical outcomes
 

 

Resources
for you

Patient guides, whitepapers, webinars
and more

Access resources
 

 

More about Navitor TAVI

Continue to the Abbott Structural Heart website for complete product information.

References
  1. Kliner D. Five-Year Outcomes of Self-expanding Intra-annular Transcatheter Heart Valve in Patients with Severe Aortic Stenosis: The Navitor IDE Study. Presented at New York Valves: The Structural Heart Summit, June 24-26, 2026. New York.
  2. Navitor TAVI Instructions for Use
Important Safety Information
Important Safety Information

Rx Only

NAVITOR™ TRANSCATHETER AORTIC VALVE IMPLANTATION SYSTEM

INDICATIONS

The Navitor™ Transcatheter Aortic Valve Implantation System is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator).

CONTRAINDICATIONS  

The valve is contraindicated for patients with inability to tolerate antiplatelet/anticoagulant therapy or nitinol alloy (nickel and titanium), or who have active infections, including endocarditis.

POTENTIAL ADVERSE EVENTS  

Adverse events potentially associated with the use of transcatheter bioprosthetic heart valves include but are not limited to: access site complications (e.g., pain, bleeding, infection, hematoma, pseudoaneurysm, etc.); acute coronary obstruction; acute myocardial infarction; allergic reaction to antiplatelet agents, contrast medium, or valve components; aortic rupture; ascending aorta trauma; atrio-ventricular node block; cardiac arrhythmias; conduction system injury; conversion to open surgical procedure; death; dissection; embolism; emergent balloon valvuloplasty; emergent percutaneous coronary intervention (PCI); emergent surgery (i.e., coronary artery bypass, heart valve replacement); endocarditis; explantation; heart failure; hemodynamic compromise; hemolysis; hemolytic anemia; hemorrhage; hypotension or hypertension; infection; myocardial ischemia; mitral valve insufficiency; multi-organ failure; non-structural dysfunction (i.e., entrapment by pannus, paravalvular leak, inappropriate sizing or positioning); pannus; pericardial effusion; perforation of the myocardium, ventricle, or a blood vessel; permanent disability; permanent pacemaker; regurgitation; renal insufficiency or renal failure; reoperation; respiratory failure; sepsis; stroke; structural deterioration (i.e., calcification, leaflet tear); thrombosis; tamponade; transfusion; valve embolization or migration; vessel dissection or spasm.